Beta Bionics (BBNX) Current Deferred Revenue (2023 - 2026)

Beta Bionics has disclosed Current Deferred Revenue across 4 years of filings, most recently posting $1.7 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $1.7 million, up 79.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 million (up 79.66% YoY), and the FY2025 annual result was $1.6 million, up 65.81% from the prior year.
• Current Deferred Revenue came in at $1.7 million for Q1 2026 at Beta Bionics, up from $1.6 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $1.7 million in Q1 2026 to a low of $87000.0 in Q4 2023.
• The 4-year median for Current Deferred Revenue is $1.1 million (2025), against an average of $1.1 million.
• Across the five-year window, Current Deferred Revenue surged 979.31% in 2024 and soared 65.81% in 2025, its largest moves.
• Beta Bionics' Current Deferred Revenue stood at $87000.0 in 2023, then soared by 979.31% to $939000.0 in 2024, then jumped by 65.81% to $1.6 million in 2025, then rose by 9.51% to $1.7 million in 2026.
• The last three Current Deferred Revenue figures came in at $1.7 million (Q1 2026), $1.6 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.